Wellington Management Group LLP Has $40.81 Million Stock Position in Corvus Pharmaceuticals, Inc. $CRVS

Key Points

• Wellington Management increased its Corvus Pharmaceuticals stake by 17.8% in the second quarter, adding 413,115 shares and bringing its holdings to 2.73 million shares valued at approximately $40.81 million.
• Institutional investors and hedge funds own 46.64% of Corvus, while corporate insiders own 19.70%; director David Moore also purchased 21,700 shares for about $250,000.
• Corvus reported a quarterly loss of $0.19 per share, missing estimates by $0.03. Despite mixed analyst opinions, the stock has a “Moderate Buy” consensus rating and a $33.33 average price target.

Wellington Management Group LLP increased its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 17.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,731,632 shares of the company's stock after purchasing an additional 413,115 shares during the period. Wellington Management Group LLP owned approximately 3.25% of Corvus Pharmaceuticals worth $40,811,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Quarry LP acquired a new stake in Corvus Pharmaceuticals during the third quarter worth approximately $27,000. Global Retirement Partners LLC bought a new position in Corvus Pharmaceuticals in the 2nd quarter valued at about $30,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Corvus Pharmaceuticals in the 2nd quarter valued at about $48,000. Russell Investments Group Ltd. acquired a new position in shares of Corvus Pharmaceuticals in the 3rd quarter valued at approximately $49,000. Finally, Sender Co & Partners Inc. acquired a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at approximately $52,000. Institutional investors and hedge funds own 46.64% of the company's stock.

Insider Buying and Selling

In other Corvus Pharmaceuticals news, Director David Moore purchased 21,700 shares of the firm's stock in a transaction on Thursday, June 11th. The stock was purchased at an average cost of $11.53 per share, for a total transaction of $250,201.00. Following the transaction, the director owned 21,700 shares in the company, valued at $250,201. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 19.70% of the stock is currently owned by corporate insiders.

Corvus Pharmaceuticals Stock Performance

NASDAQ CRVS opened at $14.39 on Friday. The firm's fifty day moving average price is $14.45 and its two-hundred day moving average price is $14.51. The stock has a market cap of $1.21 billion, a PE ratio of -23.59 and a beta of 0.87. Corvus Pharmaceuticals, Inc. has a fifty-two week low of $5.64 and a fifty-two week high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.03). As a group, sell-side analysts predict that Corvus Pharmaceuticals, Inc. will post -0.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Weiss Ratings upgraded shares of Corvus Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 28th. LADENBURG THALM/SH SH upgraded Corvus Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, July 30th. Finally, Wall Street Zen cut Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.33.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company's research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus's lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source